[Systemic inflammatory response syndrome associated with use of ticagrelor]

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Ticagrelor is a P2Y12 inhibitor used to prevent thrombotic events in acute coronary syndromes.
• While effective, its adverse effect profile includes known complications like bleeding and organ-specific issues.
• Less common adverse events associated with ticagrelor require further elucidation.

Observation:

• A case report details a patient experiencing systemic inflammatory response syndrome.
• The syndrome was observed as a secondary effect following the administration of ticagrelor.
• This highlights a potential, albeit infrequent, adverse reaction to the medication.

Findings:

• The patient's systemic inflammatory response syndrome was directly linked to ticagrelor treatment.
• This finding expands the known spectrum of ticagrelor's potential adverse effects.
• The reversible binding of ticagrelor to P2Y12 receptors is its primary mechanism of action.

Implications:

• Clinicians should be aware of systemic inflammatory response syndrome as a rare complication of ticagrelor.
• Further research may be warranted to understand the mechanisms behind this specific adverse reaction.
• This case contributes to a more comprehensive understanding of ticagrelor's safety profile.